CRISPR's bottleneck is delivery, not the editors

“Well, to be fair, there were a few visionaries who were absolutely thinking about that. Tom Cech is one of them.”

“"That is clearly not a price point that will make this available to most people that can benefit from it," she said.”

“"This is opening the door to lots of things now that can be done to both address challenges of climate change, dealing with drought conditions, introducing traits in the plants that give…”

“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”

“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”

“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”